TY  - BOOK
AU  - Moghul, M.
AU  - Rhudd, A.
AU  - Rai, B.
TI  - Gallium labelled-prostate-specific membrane antigen-positron emission tomography/computed tomography (GA-PSMA-PET/CT) vs. choline-PET/CT in malignant prostate cancer: a systematic review
PY  - 2017///
N1  - NMUH Staff Publications; EMBASE; 31
N2  - <span style="font-size: 10pt;"><span style="color: #4a4a4a; font-family: Lato, "Helvetica Neue", Helvetica, Arial, sans-serif; text-decoration-color: initial;">Introduction&Objective: Recently the role of Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) has become more prominent in helping to diagnose recurrent prostate cancer and malignant prostate cancer. The role of PSMA as a radiotracer appears to be surpassing that of choline tracers in prominent centres. We have evaluated current data regarding the use of PSMA-PET/CT scans compared to Choline PET/CT scans. Materials and Methods: We performed a review of PubMed/Medline, Clinical trials.gov and the Cochrane Library in March 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Results: 4 studies were included in this review having directly compared 68GA-PSMA-PET/CT and Choline PET/CT scans. Choline tracers used were 11C in one study and 18F in the other studies. Overall 230 men had both 68GA-PSMA PET and choline-PET/CT scans. Overall detection rates for biochemical recurrence were 81.1% for GA-PSMA-PET and 70.3% for choline-PET/CT. This indicates that GA-PSMA PET/CT is significantly better than choline-PET/CT for detecting recurrence of prostate cancer (P < 0.005). 68GA-PSMA-PET/CT also showed higher detection rates at lower PSA values. Lesions missed on PSMAPET/CT but captured by choline-PET/CT were found to be negligible (1-2%). Conclusions: 68GA-PSMA-PET/CT appears to offer better diagnostic capability than choline-PET/CT, as well as similar if not higher sensitivities and specificities, indicating justification for replacing choline as the radiotracer of choice in prostate cancer and guiding further management decisions.</span> [Conference abstract]</span&gt
UR  - https://www.liebertpub.com/doi/pdf/10.1089/end.2017.29029.abstracts
ER  -